HK Inno.N FY 2025 Annual ReportBeta
HK Inno.N annual report for FY 2025, filed with DART (Korea Financial Supervisory Service) on March 18, 2026. This page provides AI-powered English analysis including business overview, management discussion & analysis (MD&A), risk factors, and KIFRS consolidated financial data such as revenue, net income, gross margin, operating margin, and return on equity (ROE).
HK Inno.N FY 2025 Annual Report Analysis
Business Overview
- • 2025 revenue KRW 1.06T, operating profit KRW 110.9B; 93% from prescription drugs, 7% from H products
- • K-CAB sales KRW 195.7B, expanded global launch in USA, China, India, Latin America as of 2025
Management Discussion & Analysis
- • Revenue KRW 1,063.2B (+18.5% YoY); operating profit KRW 110.9B (+25.7%); net income KRW 75.7B (+22.9%)
- • Prescription drug segment revenue up KRW 180.7B (+22.5%) driven by K-CAB sales increase of KRW 31.7B and infusion products +KRW 23.0B
Risk Factors
- • KRW 882M post-tax profit/capital impact for 10% USD exchange rate rise, up from KRW 743M prior year
- • KRW 1.07B post-tax profit/capital sensitivity to 1% variable interest rate increase on borrowings, up from KRW 881M
Source: DART (Korea Financial Supervisory Service) · AI summaries generated from the original Korean filing (English output) · Beta: coverage is expanding